CC-486

Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

Retrieved on: 
Thursday, September 12, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical research, Health, Clinical trials, Articles, Medical statistics, Medicine, Mind–body interventions, Clinical endpoint, Celgene, Placebo-controlled study, Placebo, QUAZAR AML-001, CC-486, AML, Celgene

Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.

Key Points: 
  • Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
  • The study demonstrated that maintenance treatment with CC-486 resulted in a highly statistically significant and clinically meaningful improvement in overall survival compared to placebo.
  • The key secondary endpoint of relapse-free survival (RFS) also showed a statistically significant improvement.
  • Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control.